Duragesic Risk Management Negotiations Ongoing After FDA Health Advisory
Executive Summary
Creation of a risk management plan for Johnson & Johnson's Duragesic and generics could be the next regulatory step for the product after FDA's release of a Public Health Advisory on fentanyl overdoses
You may also be interested in...
Limits Of Risk Management Practices Shown In Renewed Duragesic Warnings
FDA's approach to continued reports of deaths from fentanyl patches illustrates the challenges that the agency will face in managing drug risks even as it wields the new powers granted by the FDA Amendments Act
Limits Of Risk Management Practices Shown In Renewed Duragesic Warnings
FDA's approach to continued reports of deaths from fentanyl patches illustrates the challenges that the agency will face in managing drug risks even as it wields the new powers granted by the FDA Amendments Act
Purdue Withdraws Palladone; FDA Evaluating Other Extended-Release Opiates
FDA is evaluating the potential for an alcohol interaction with other sustained-release opiates following the withdrawal of Purdue Pharma's Palladone due to the potential for serious alcohol-related adverse events